Objective: To evaluate treatment of mitral regurgitation (MR) in patients with severe degenerative MR (DMR) at prohibitive surgical risk undergoing transcatheter mitral valve repair with the MitraClip. Background: Surgical mitral valve repair remains the gold standard for severe DMR. However, the results with MitraClip in prohibitive risk DMR patients have not been previously reported. Methods: A prohibitive risk DMR cohort was identified by a multi-disciplinary heart team that retrospectively evaluated high risk DMR patients enrolled in the EVEREST II studies. Results: 141 high risk DMR patients were consecutively enrolled; 127 of these patients were retrospectively identified as meeting the definition of prohibitive risk and had one-year follow-up (median 1.47 years) available. Patients were elderly (mean age 82 years), severely symptomatic (87% NYHA Class III/IV), and at prohibitive surgical risk (STS score 13.2±7.3%). MitraClip was successfully implanted in 95.3%; hospital stay was 2.9±3.1 days. Major adverse events at 30 days included death in 6.3%, myocardial infarction in 0.8%, and stroke in 2.4%. Through 1 year there were a total of 30 (23.6%) deaths, with no survival difference between patients discharged with MR ≤1+ or MR=2+. A majority of surviving patients (82.9%) remained MR ≤2+ at 1 year and 86.9% were in NYHA Functional Class I or II. Left ventricular end-diastolic volume decreased (125.1±40.1 ml to 108.5±37.9 ml, p<0.0001, N=69 survivors with paired data). SF-36 quality-of-life scores improved and hospitalizations for heart failure were reduced in patients whose MR was reduced. Conclusions: Transcatheter mitral valve repair in prohibitive surgical risk patients is associated with safety and good clinical outcomes, including rehospitalization decrease, functional improvements and favorable ventricular remodeling at 1 year.
Statistical Analysis. Continuous data are summarized as mean ± standard deviation (SD) and paired comparisons are performed using the paired t-test. . . Kaplan-Meier method is used for survival analysis. Pairwise comparisons of survival by discharge MR were performed using logrank tests. SF-36 surveys were scored using standard methods. SF-36 summary scores are reported using the norm-based scoring (population mean=50, population standard deviation=10, higher=better), while SF-36 sub-scales are reported according to their original 0-100 scales (higher=better). Pairwise comparisons using the chi-square test were performed on two-sample proportions to assess the relationship between discharge MR severity and NYHA Functional
Class at 1 year. The rate of hospitalization for heart failure (HF) is estimated and evaluated using a Poisson regression model with length of follow-up post-discharge as an offset. In all analyses, a p-value <0.05 is considered statistically significant.
RESULTS
Baseline characteristics: Table 1 shows baseline demographics and comorbidities for the Prohibitive Risk DMR Cohort.
The patients had poor functional status: 87% were NYHA Class III/IV at baseline. As expected, SF-36 quality of life scores were well below population norms. Measures of physical function in particular were markedly reduced: the mean physical component summary (PCS) score was 32.0 points at baseline, nearly a full standard deviation below the age-adjusted (age ≥75 years) US norm of 39.9.(5) Likewise, the mean mental component summary (MCS) score of 46.1 was below the age-adjusted population norm of 50.2 for the MCS score.
The reasons for prohibitive risk are summarized in Table 2 . A majority of patients (78/127 or 61.4%) presented with more than 1 prohibitive risk factor. The median age of patients who died prior to 30 days was 86 years; 3 were female and 5 were male. Four (4) of the 8 patients received 2 MitraClips, 2 patients received 1 MitraClip and 2 patients did not receive any MitraClips. Mean predicted surgical mortality risk of the 8 patients (using STS v 2.73 replacement score) was 17.6%. Six (6) deaths were clinical event committeeadjudicated as cardiac-related, and 1 of these was further adjudicated as device-related due to a prolonged procedure. Reasons for the 8 deaths included septic shock (n=1), existing comorbidities (n=2), GI bleed (n=1), renal failure and cardiac tamponade (n=1), myocardial infarction (n=1), vascular bleeding (n=1) and stroke (n=1).
There have been no reports of a MitraClip device embolization or single leaflet device attachment (SLDA) in the Prohibitive Risk DMR Cohort through the observed follow-up (median 1.47 years).
Post-procedural status and length of hospital stay:
The mean post-procedure length of stay in the intensive care unit was 1.4 ± 1.8 days. The average length of hospital stay was 2.9 ± 3.1 days. Despite the elderly and highly comorbid nature of this population, 88% of prohibitive risk DMR patients were discharged home following the MitraClip procedure.
MR severity: Figure 1a shows MR severity at baseline and discharge in patients with paired measurements available (patients in the REALISM continued access study were permitted to enroll based on site-determined MR severity, which underwent subsequent assessment by the Reduction of MR to 2+ or less at discharge was associated with a higher probability of being alive with NYHA Functional Class I/II at 1 year (71.7% of patients discharged with MR ≤ 1+, 69.7% of patients discharged with MR = 2+, and 36.8% of patients discharged with MR 3+ or 4+) compared to continued or untreated severe MR at discharge. There was no statistically significant difference in the probability of NYHA Class I/II at 1 year between the discharge MR ≤ 1+ and MR = 2+ groups. Additionally, the probabilities of NYHA Class I/II at 1 year in the MR ≤ 1+ and the MR = 2+ groups were significantly different than in the MR = 3+/4+ group (p=0.013 and p=0.044, respectively).
Left ventricular function:
Compared with baseline, left ventricular end-diastolic volume decreased significantly, from 125.1 ± 40.1 ml to 108.5 ± 37.9 ml at 12 months (p < 0.0001) in survivors with paired data (N=69). Left ventricular end-systolic volume decreased from 49.1 ± 24.5 ml to 46.1 ± 21.4 ml at 12 months (p = 0.07) in survivors with paired data (N=69).
DISCUSSION
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This is the first report on the use of the MitraClip specifically in patients with DMR considered at prohibitive risk for mitral valve surgery. In this population, as in others, the MitraClip procedure had a high (95%) initial success rate with a low rate of serious complications, 30-day mortality, and subsequent mitral valve surgery. A large majority of these patients achieved reduction in their MR to 2+ or less, and this was associated with improvements in NYHA functional class and quality of life, reductions in heart failure hospitalization, and LV reverse remodeling. In addition, patients with 2+ residual MR at discharge were found to have similar survival to those with ≤1+ MR, with both of those groups having better survival than patients with 3+/4+ MR at discharge.
Since transcatheter MV repair with the MitraClip was first described by St. Goar et al (7) The increased operative risk is related not to the patients' mitral valve disease, but rather to the person "wrapped around" the regurgitant valve. Despite their risk, the procedural outcomes were favorable, with no intraprocedural deaths, few device related complications, safety results not worse than for surgery in the lower risk randomized trial, a procedure time of approximately 2.5 hours on average, and a procedure success rate of more than 95%. In terms of resource utilization, it is also impressive that in an elderly population with multiple co-morbidities the hospital length of stay following the MitraClip procedure was approximately 3 days, with nearly 90% discharged to home. These resource patterns suggest that MitraClip procedures may be less expensive than mitral valve surgery would be for similar patients. (8) One of the points of concern that has been raised previously in comparison to open mitral valve surgery is that the MitraClip achieves a lesser degree of MR reduction. In this prohibitive risk cohort of patients, nearly 80% of patients with 3+ or 4+ MR at baseline achieved a MR reduction to <2+ at time of discharge. Were these patients at lower operative risk, it is likely that highly It is important that this study did not find a marked difference in patient outcomes between the groups with 1+ residual MR versus those with 2+ residual MR. In both cases, there were significant improvements compared to those with 3+ or 4+ residual MR. It is likely that for such a high risk comorbid cohort, being able to achieve MR reduction to below surgical referral standards without the biologic cost of a more invasive approach is a success on the individual level.
Limitations. These data encompass the early experience with MitraClip, and are thus limited by relative inexperience of the individual MitraClip operators in the U.S. This data was also limited in that it was not completely from a randomized trial, due to not having a control arm to randomize to (as medical therapy lacks a treatment role in degenerative MR, and surgical options are not standard in prohibitive surgical risk patients). Because the cohort was retrospectively identified, all analyses were post-hoc.Another limitation is that follow-up echocardiographic and M A N U S C R I P T
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16 functional data were obtained and reported for surviving patients only. No imputation for deceased patients' data was performed, although deaths and missing data were accounted for in the present study.
CONCLUSION
MitraClip therapy is safe in patients with severe degenerative (primary) MR for whom a heart team has determined that mitral valve surgery is associated with a prohibitive risk/benefit ratio.
Transcatheter reduction of degenerative MR in these patients provides significant benefits including improvements in symptoms and functional status, a decrease in hospitalizations, and favorable LV remodeling at 1 year. 
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